Treatment of Scan-Negative, Thyroglobulin-Positive Metastatic Thyroid Cancer Using Radioiodine 131I and Recombinant Human Thyroid Stimulating Hormone--Authors' Responseh

1997 ◽  
Vol 82 (12) ◽  
pp. 4277b-4278 ◽  
Author(s):  
A. Z. Rudavsky
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Metastatic Thyroid Cancer ◽  
Stimulating Hormone

scholarly journals Targeting the TSH receptor in thyroid cancer

2017 ◽  
Vol 24 (6) ◽  
pp. R191-R202 ◽  
Author(s):  
Christopher W Rowe ◽  
Jonathan W Paul ◽  
Craig Gedye ◽  
Jorge M Tolosa ◽  
Cino Bendinelli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Molecular Basis ◽  
Risk Profile ◽  
Thyroid Stimulating Hormone ◽  
Human Thyroid ◽  
Oncogenic Pathway ◽  
Cancer Metastases ◽  
Thyroid Cancer Metastases ◽  
Metastatic Thyroid Cancer ◽  
Stimulating Hormone

Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

Sign in / Sign up

Export Citation Format

Share Document